Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
Rhea-AI Summary
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the upcoming Ladenburg Oncology Innovators & Investors Symposium.
CFO Raphi Levy will represent the company at this virtual event, scheduled for December 12, 2024, from 11:00 AM to 11:25 AM EST. The format will include both a presentation and one-on-one meetings, which can be arranged through Ladenburg representatives.
Positive
- None.
Negative
- None.
News Market Reaction – DRTS
On the day this news was published, DRTS declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium.
| Event: | Ladenburg Oncology Innovators & Investors Symposium |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | December 12, 2024 |
| Time: | 11:00AM – 11:25AM EST |
| Location: | Virtual |
Please reach out to your Ladenburg representative to schedule 1-on-1 meetings with Mr. Levy.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact: IR@alphatau.com
FAQ
When is Alpha Tau Medical (DRTS) presenting at the Ladenburg Oncology Symposium?
Who will represent Alpha Tau Medical (DRTS) at the Ladenburg Symposium?
What is the format of Alpha Tau's (DRTS) participation in the Ladenburg Symposium?
How can investors arrange meetings with Alpha Tau (DRTS) at the Ladenburg Symposium?
